[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aura Biosciences Inc (AURA)

Aura Biosciences Inc (AURA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 785,741
  • Shares Outstanding, K 103,387
  • Annual Sales, $ 0 K
  • Annual Income, $ -106,190 K
  • EBIT $ -119 M
  • EBITDA $ -118 M
  • 60-Month Beta 0.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.58

Options Overview Details

View History
  • Implied Volatility 290.32% (-5.42%)
  • Historical Volatility 69.23%
  • IV Percentile 32%
  • IV Rank 17.05%
  • IV High 1,343.19% on 01/12/26
  • IV Low 73.97% on 01/13/26
  • Expected Move (DTE 25) 1.45 (19.01%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 20
  • Volume Avg (30-Day) 190
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 3,763
  • Open Int (30-Day) 2,477
  • Expected Range 6.16 to 9.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.41
  • Number of Estimates 3
  • High Estimate $-0.31
  • Low Estimate $-0.50
  • Prior Year $-0.47
  • Growth Rate Est. (year over year) +12.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.65 +14.29%
on 04/30/26
9.53 -20.29%
on 05/05/26
+0.11 (+1.47%)
since 04/22/26
3-Month
5.24 +45.01%
on 02/23/26
9.53 -20.29%
on 05/05/26
+2.19 (+40.48%)
since 02/20/26
52-Week
4.73 +60.68%
on 01/20/26
9.53 -20.29%
on 05/05/26
+1.66 (+27.95%)
since 05/22/25

Most Recent Stories

More News
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data

Aura Biosciences (NASDAQ:AURA) executives outlined the company’s strategy for its lead candidate bel-sar during a session at the H.C. Wainwright Connect Conference, emphasizing ocular oncology as the...

AURA : 7.60 (-0.65%)
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors...

AURA : 7.60 (-0.65%)
Aura Biosciences to Participate in Upcoming Investor Conferences

BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function,...

AURA : 7.60 (-0.65%)
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights

Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors ...

AURA : 7.60 (-0.65%)
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve...

AURA : 7.60 (-0.65%)
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve...

AURA : 7.60 (-0.65%)
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve...

AURA : 7.60 (-0.65%)
Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion

Natalie Holles, seasoned industry executive with significant rare disease operational and commercialization experience, appointed Chief Executive Officer and President and member of the Board of Directors...

AURA : 7.60 (-0.65%)
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 ...

AURA : 7.60 (-0.65%)
Aura Biosciences Has Been Quietly Telling a New Story. Earnings Day Is When the Market Decides If It Believes It.

Barchart Research What to Expect from AURA Earnings AURA Generated March 27, 2026 Current Price $6.27 EPS Estimate $-0.43 Consensus Rating Strong Buy Average Move 3.65% Aura Biosciences Has Been Quietly...

AURA : 7.60 (-0.65%)

Business Summary

Aura Biosciences Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system. The company's lead product candidate includes AU-011. Aura Biosciences Inc. is based...

See More

Key Turning Points

3rd Resistance Point 8.09
2nd Resistance Point 7.98
1st Resistance Point 7.79
Last Price 7.60
1st Support Level 7.50
2nd Support Level 7.39
3rd Support Level 7.20

See More

52-Week High 9.53
Fibonacci 61.8% 7.70
Last Price 7.60
Fibonacci 50% 7.13
Fibonacci 38.2% 6.57
52-Week Low 4.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.